LoadingLoadingLoadingNo insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
AQR
$229.0M
added
Millennium
$218.9M
added
Sells/Trims (1)
D.E. Shaw
$109.6M
trimmed
Sells (2)
No tracked top-trader positions in VRTX as of Oct 21, 17:10 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 3, 2026
Financial period
Q2 2026
Earnings per share
$4.75 expected
Revenue
$3.22B expected
FY2026 guidance
$13.10B to $13.20B
No comparable estimate
Estimates as of Oct 21, 2026
EPS expected
-$29.51 to $5.06
Revenue expected
13 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 3, 2026 | $4.73 / $4.75Yahoo Finance | -0.32% in line | $3.33B $3.22B expected | +3.43% beat |
| Mar 31, 2026 | May 4, 2026 | $4.47 / $4.31Yahoo Finance | +3.81% beat | $2.99B No estimate | Unavailable |
| Dec 31, 2025 | Feb 12, 2026 | $5.03 / $5.15Yahoo Finance | -2.30% miss | $3.23B No estimate | Unavailable |
| Sep 30, 2025 | Nov 3, 2025 | $4.80 / $4.58Yahoo Finance | +4.87% beat | $3.08B No estimate | Unavailable |
| Jun 30, 2025 | Aug 4, 2025 | $4.52 / $4.25Alpha Vantage | +6.35% beat | $2.96B No estimate | Unavailable |
| Mar 31, 2025 | May 5, 2025 | Unavailable | - | $2.77B No estimate | Unavailable |
| Dec 31, 2024 | Feb 10, 2025 | $3.98 / $4.02Alpha Vantage | -0.99% in line | $2.91B No estimate | Unavailable |
| Sep 30, 2024 | Nov 4, 2024 | $4.38 / $4.13Alpha Vantage | +6.05% beat | $2.77B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.08B | $3.23B | $2.99B | $3.33B |
| Cost of what it sold | $414.8M | $466.0M | $392.8M | $489.2M |
| Gross profit | $2.66B | $2.76B | $2.59B | $2.84B |
| What it spent | ||||
| Research and development | $1.03B | $973.7M | $961.6M | $993.8M |
| Sales and admin | $445.1M | $487.0M | $493.7M | $582.2M |
| Other operating costs | — | — | — | $21.8M |
| Total operating expenses | $1.48B | $1.46B | $1.46B | $1.60B |
| What was left | ||||
| Operating profit | $1.19B | $1.30B | $1.14B | $1.25B |
| Interest on debt | $3.3M | $3.3M | — | — |
| Profit before tax | $1.30B | $1.33B | $1.25B | $1.39B |
| Tax | $215.9M | $139.9M | $221.5M | $292.0M |
| Net profit | $1.08B | $1.19B | $1.03B | $1.10B |
| EBITDA | $1.36B | $1.39B | $1.31B | $1.45B |
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Vertex Pharma stock trades at EUR 445.78 as Vertex reports ALYFTREK data
Leans bullishOct 18Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data
BullishOct 17ACADIA Pharmaceuticals stock has a USD 31.34 consensus target from 18 analysts
NeutralOct 17ACADIA Pharmaceuticals stock has a USD 31.34 consensus target from 18 analysts
NeutralOct 17Krystal Biotech stock falls 4.1 percent, 17.2 percent below high
NeutralOct 17Vertex Pharmaceuticals reports ALYFTREK data in young children
BullishOct 17Vertex Pharma stock: Citi keeps USD 585.00 target for Vertex Pharma stock
Leans bullishOct 16Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
BearishOct 16
